Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Summary

This multi-site, Phase 1/2 clinical trial is an open-label study to identify the safety, pharmacokinetics, and efficacy of a repeated dose regimen of NEO212 alone for the treatment of patients with radiographically-confirmed progression of Astrocytoma IDH- mutant, Glioblastoma IDH-wildtype, and the safety, pharmacokinetics and efficacy of a repeated dose regimen of NEO212 when given with select SOC for the treatment of solid tumor patients with radiographically confirmed uncontrolled metastases to the brain. The study will have three phases, Phase 1, Phase 2a and Phase 2b.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• Diffuse Astrocytoma, IDH-Mutant
• Glioblastoma, IDH-wildtype
• Brain Metastases, Adult
• Cervical Cancer
• Colorectal Cancer
• Esophageal Cancer
• Esophageal Squamous Cell Carcinoma
• Gastric Cancer
• Gastroesophageal Junction Adenocarcinoma
• Head and Neck Squamous Cell Carcinoma
• Melanoma
• Merkel Cell Carcinoma
• Microsatellite Instability-High Solid Malignant Tumor
• Mismatch Repair Deficient Solid Malignant Tumor
• Microsatellite Instability-High Colorectal Cancer
• Mismatch Repair Deficient Colorectal Cancer
• Non-small Cell Lung Cancer
• Renal Cell Carcinoma
• Small Cell Lung Cancer
• Squamous Cell Carcinoma
• Urothelial Carcinoma

Eligibility basics and study details

Study type

Interventional

Phase

Phase 1/2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Neonc Technologies, Inc.

Last updated on ClinicalTrials.gov

September 24, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites